Vaccination against PD-L1 with IO103 a Novel Immune Modulatory Vaccine in Basal Cell Carcinoma: A Phase IIa Study

Autor: Nicolai Grønne Jørgensen, Mads Hald Andersen, Signe Ledou Nielsen, Özcan Met, Lone Skov, Inge Marie Svane, Jacob Handlos Grauslund, Jeanette Kaae, Eva Ehrnrooth, Claus Zachariae, Ayako Wakatsuki Pedersen
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Zdroj: Cancers
Cancers, Vol 13, Iss 911, p 911 (2021)
Volume 13
Issue 4
Jørgensen, N G, Kaae, J, Grauslund, J H, Met, Ö, Nielsen, S L, Pedersen, A W, Svane, I M, Ehrnrooth, E, Andersen, M H, Zachariae, C & Skov, L 2021, ' Vaccination against pd-l1 with io103 a novel immune modulatory vaccine in basal cell carcinoma : A phase iia study ', Cancers, vol. 13, no. 4, 911, pp. 1-15 . https://doi.org/10.3390/cancers13040911
ISSN: 2072-6694
Popis: Simple Summary Basal cell carcinoma is the most common skin cancer and new treatments for patients with widespread and numerous tumors are lacking. In a previous study treating patients with multiple myeloma with a peptide vaccine called IO103 against an immune checkpoint molecule called programmed death ligand 1, two cases of basal cell carcinoma regressed. The aim of the present study was to assess the effect of vaccination with IO103 in ten patients with basal cell carcinoma. Patients were vaccinated with Montanide as adjuvant up to nine times during six months. Regression in tumor size of at least 30% was seen in five of 18 tumors, two of which showed complete regression. Vaccinations resulted in immune responses against the vaccine in blood samples from nine of ten patients and in skin samples from five of nine patients. The findings suggest that the vaccine may be effective against some basal cell carcinomas. Abstract Antitumor activity of immune checkpoint blocking antibodies against programmed death 1 (PD-1) in basal cell carcinoma (BCC) has been described. IO103 is a peptide vaccine against the major PD-1 ligand PD-L1. A phase IIa study of vaccination with IO103 and Montanide adjuvant was conducted in patients with resectable BCC (NCT03714529). Vaccinations were given six times every 2 weeks (q2w), followed by three vaccines q4w in responders. Primary endpoints were clinical responses of target tumors, change in target tumor size and immune responses to the vaccine. Secondary endpoint was safety. One tumor per patient was designated target tumor and biopsied twice during the course of vaccination. Synchronous non-target BCCs were not biopsied during vaccinations. Ten patients were vaccinated (six patients received six vaccinations and four patients received nine vaccinations). A partial response (PR) was seen in two target tumors. Two complete responses (CR) and one PR were observed in eight non-target tumors in four patients. No tumors progressed. Related adverse events were grade 1 and reversible. Immune responses against IO103 were induced in blood samples from nine of ten and skin-infiltrating lymphocytes from five of the nine patients. The regressions seen in non-target tumors suggest that IO103 may be effective against a subtype of BCC.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje